Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 19/20 | 0.67 |
| ▸ | EDNRA | P25101 | 19/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.58 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030353 | 1.00 | EDNRB (0.67) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL10316295 | 0.93 | EDNRB (0.70) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3019873 | 0.90 | EDNRB (0.82) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3019879 | 0.90 | EDNRB (0.82) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2356501 | 0.84 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2352546 | 0.84 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3023827 | 0.84 | EDNRB (0.83) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3023829 | 0.84 | EDNRB (0.83) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL1068402 | 0.83 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2350734 | 0.83 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217155-B2 | Metabolites and derivatives of ambrisentan | GILEAD COLORADO, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20100204163-A1 | METABOLITES AND DERIVATIVES OF AMBRISENTAN | GILEAD COLORADO, INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204163-A1 | METABOLITES AND DERIVATIVES OF AMBRISENTAN | EDNRA, UGT1A3, EDNRB | EDNRB 3/4885EDNRA 1/4885NR1I2 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.